CUFinder

FOLEFAC AMINKENG

About FOLEFAC AMINKENG

FOLEFAC AMINKENG, With an exceptional h-index of 18 and a recent h-index of 16 (since 2020), a distinguished researcher at National University of Singapore, specializes in the field of Genomics, Pharmacogenomics and Precision Health.

His recent articles reflect a diverse array of research interests and contributions to the field:

P2. 05-05 Genomic Variants Associated with Response to Immune Checkpoint Inhibitors Amongst Asian Patients with Advanced NSCLC

An introductory tutorial on cardiovascular pharmacogenetics for healthcare providers

Factors Predictive of Primary Resistance to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer

A Non-Coding Variant in LOC105371512 Confers Susceptibility to Bleomycin-Induced Lung Injury

Real‐world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non‐small cell lung cancer

EP08. 01-101 Factors Predictive of Primary Resistance to Immune Checkpoint Inhibitors in Asian Patients with Advanced NSCLC

Pharmacogenomic prediction of immune-related adverse events from immune checkpoint inhibitors among Asian patients.

Risk factors for immune‐related adverse events from anti‐PD‐1 or anti‐PD‐L1 treatment in an Asian cohort of nonsmall cell lung cancer patients

FOLEFAC AMINKENG Information

University

Position

/ National University Health System Singapore

Citations(all)

1426

Citations(since 2020)

992

Cited By

845

hIndex(all)

18

hIndex(since 2020)

16

i10Index(all)

30

i10Index(since 2020)

20

Email

University Profile Page

Google Scholar

FOLEFAC AMINKENG Skills & Research Interests

Genomics

Pharmacogenomics and Precision Health

Top articles of FOLEFAC AMINKENG

P2. 05-05 Genomic Variants Associated with Response to Immune Checkpoint Inhibitors Amongst Asian Patients with Advanced NSCLC

Journal of Thoracic Oncology

2023/11/1

Y Huang
Y Huang

H-Index: 9

An introductory tutorial on cardiovascular pharmacogenetics for healthcare providers

Clinical Pharmacology & Therapeutics

2023/8

Sony Tuteja
Sony Tuteja

H-Index: 13

Folefac Aminkeng
Folefac Aminkeng

H-Index: 13

Deepak Voora
Deepak Voora

H-Index: 22

Factors Predictive of Primary Resistance to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer

Cancers

2023/5/12

Yiqing Huang
Yiqing Huang

H-Index: 5

Yu Yang Soon
Yu Yang Soon

H-Index: 13

Folefac Aminkeng
Folefac Aminkeng

H-Index: 13

A Non-Coding Variant in LOC105371512 Confers Susceptibility to Bleomycin-Induced Lung Injury

Blood

2022/11/15

Hossein Tabatabaeian
Hossein Tabatabaeian

H-Index: 11

Sanjay De Mel
Sanjay De Mel

H-Index: 13

Bin Zhang
Bin Zhang

H-Index: 2

Tiffany Tang
Tiffany Tang

H-Index: 5

Kee Yuan Ngiam
Kee Yuan Ngiam

H-Index: 14

Folefac Aminkeng
Folefac Aminkeng

H-Index: 13

Real‐world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non‐small cell lung cancer

Thoracic Cancer

2022/11

Yiqing Huang
Yiqing Huang

H-Index: 5

Yu Yang Soon
Yu Yang Soon

H-Index: 13

Folefac Aminkeng
Folefac Aminkeng

H-Index: 13

EP08. 01-101 Factors Predictive of Primary Resistance to Immune Checkpoint Inhibitors in Asian Patients with Advanced NSCLC

Journal of Thoracic Oncology

2022/9/1

Y Huang
Y Huang

H-Index: 9

Pharmacogenomic prediction of immune-related adverse events from immune checkpoint inhibitors among Asian patients.

2022/6/1

Yiqing Huang
Yiqing Huang

H-Index: 5

Folefac Aminkeng
Folefac Aminkeng

H-Index: 13

Risk factors for immune‐related adverse events from anti‐PD‐1 or anti‐PD‐L1 treatment in an Asian cohort of nonsmall cell lung cancer patients

International journal of cancer

2022/2/15

Yiqing Huang
Yiqing Huang

H-Index: 5

Yu Yang Soon
Yu Yang Soon

H-Index: 13

Folefac Aminkeng
Folefac Aminkeng

H-Index: 13

Cytokine release syndrome in cancer patients receiving immune checkpoint inhibitors: a case series of 25 patients and review of the literature

2022/1/28

Folefac Aminkeng
Folefac Aminkeng

H-Index: 13

Yiqing Huang
Yiqing Huang

H-Index: 5

Anselm Mak
Anselm Mak

H-Index: 30

Neutrophil-to-lymphocyte ratio predicts development of immune-related adverse events and outcomes from immune checkpoint blockade: a case-control study

Cancers

2021/1

Mark Muthiah
Mark Muthiah

H-Index: 5

Anselm Mak
Anselm Mak

H-Index: 30

Horng Ruey Chua
Horng Ruey Chua

H-Index: 14

Eng Soo Yap
Eng Soo Yap

H-Index: 8

Folefac Aminkeng
Folefac Aminkeng

H-Index: 13

Yiqing Huang
Yiqing Huang

H-Index: 5

P75. 10 Risk Factors for Immune-Related Adverse Events from Anti-PD-1/PD-L1 Treatment in an Asian Cohort of NSCLC Patients

2021/3/1

Y Huang
Y Huang

H-Index: 9

See List of Professors in FOLEFAC AMINKENG University(National University of Singapore)